Farmaceutisch concern · België
UCB
Een concern van 29 bedrijven met 372 geneesmiddelen in 9 landen.
Concernstructuur
29 bedrijven in 13 landen
Laden…
Farmaceutisch concern · België
Een concern van 29 bedrijven met 372 geneesmiddelen in 9 landen.
29 bedrijven in 13 landen
Eén gratis account voor de Prognia-apps: Ward om te studeren, Osler voor klinische antwoorden met hun bronnen, en het netwerk om je collega’s te vinden.
Prognia stelt concerns samen uit de namen die toezichthouders publiceren en uit koppelingen tussen bedrijven; het is geen officiële concernstructuur.
Alle geneesmiddelen van alle bedrijven in het concern, actuele eerst.
1–25 van 372
| Geneesmiddel | Werkzame stof | Land | Status | Toelating |
|---|---|---|---|---|
| ATARAX 2 mg/ml JARABE200 mg · Jarabe | Hidroxizina dihidrocloruro | Spanje | In de handel | 1956 |
| ATARAX 25 mg COMPRIMIDOS RECUBIERTOS CON PELICULA25 mg · Comprimido recubierto con película | Hidroxizina dihidrocloruro | Spanje | In de handel | 1956 |
| BIMZELX160ml · Injectable | Bimekizumab | Verenigde Staten | In de handel | 2023 |
| BIMZELX320 mg / 2 ml · Solution | Bimekizumab | Canada | In de handel | 2025 |
| Bimzelx320mg/2ml (160mg/2ml) · Injection | Bimekizumab | Verenigde Staten | In de handel | 2024 |
| BIMZELX160 mg / ml · Solution | Bimekizumab | Canada | In de handel | 2022 |
| BIMZELX | Bimekizumab | Brazilië | Toegelaten | 2023 |
| Bimzelx160mg/ml · Injection | Bimekizumab | Verenigde Staten | In de handel | 2023 |
| BIMZELX320 mg / 2 ml · Solution | Bimekizumab | Canada | In de handel | 2025 |
| Bimzelx320mg/2ml (160mg/2ml) · Injection | Bimekizumab | Verenigde Staten | In de handel | 2024 |
| Bimzelx | Bimekizumab | EU (EMA) | Toegelaten | 2021 |
| BIMZELX160 mg / ml · Solution | Bimekizumab | Canada | In de handel | 2022 |
| Bimzelx 160 mg/ml, oplossing voor injectie in een voorgevulde penOplossing voor injectie | Bimekizumab | Nederland | Toegelaten | 2021 |
| Bimzelx 160 mg/ml, oplossing voor injectie in een voorgevulde spuitOplossing voor injectie | Bimekizumab | Nederland | Toegelaten | 2021 |
| BIMZELX 160 MG SOLUCION INYECTABLE EN JERINGA PRECARGADA160 mg · Solución inyectable en jeringa precargada | Bimekizumab | Spanje | In de handel | 2021 |
| BIMZELX 160 MG SOLUCION INYECTABLE EN PLUMA PRECARGADA160 mg · Solución inyectable en pluma precargada | Bimekizumab | Spanje | In de handel | 2021 |
| Bimzelx 320 mg oplossing voor injectie in een voorgevulde penOplossing voor injectie | Bimekizumab | Nederland | Toegelaten | 2021 |
| Bimzelx 320 mg oplossing voor injectie in een voorgevulde spuitOplossing voor injectie | Bimekizumab | Nederland | Toegelaten | 2021 |
| BIMZELX 320 MG SOLUCION INYECTABLE EN PLUMA PRECARGADA320 mg · Solución inyectable en pluma precargada | Bimekizumab | Spanje | In de handel | 2024 |
| BIPHETAMINE 12.56.25mg base; 6.25mg base · Capsule, extended release | Amphetamine resin complex, Dextroamphetamine resin complex | Verenigde Staten | Niet in de handel | 1955 |
| BIPHETAMINE 2010mg base; 10mg base · Capsule, extended release | Amphetamine resin complex, Dextroamphetamine resin complex | Verenigde Staten | Niet in de handel | 1955 |
| BIPHETAMINE 7.53.75mg base; 3.75mg base · Capsule, extended release | Amphetamine resin complex, Dextroamphetamine resin complex | Verenigde Staten | Niet in de handel | 1955 |
| BRIVIACT50mg/5ml (10mg/ml) · Solution | Brivaracetam | Verenigde Staten | In de handel | 2016 |
| BRIVIACT100mg | 10mg | 25mg | 50mg | 75mg · Tablet | Brivaracetam | Verenigde Staten | In de handel | 2016 |
| BRIVIACT10mg/ml · Solution | Brivaracetam | Verenigde Staten | In de handel | 2016 |
Waar het geneesmiddelen registreert of maakt, en hoeveel daarvan actueel zijn.
| Land | Geneesmiddelen | Actueel | Vroeger | Bedrijven |
|---|---|---|---|---|
| Spanje | 107 | 102 | 5 | BedrijvenAlle geneesmiddelen |
| Brazilië | 93 | 9 | 84 | BedrijvenAlle geneesmiddelen |
| Nederland | 53 | 53 | 0 | BedrijvenAlle geneesmiddelen |
| Verenigde Staten | 43 | 43 | 0 | BedrijvenAlle geneesmiddelen |
| Canada | 38 | 34 | 4 | BedrijvenAlle geneesmiddelen |
| Europese Unie (EMA) | 16 | 13 | 3 | BedrijvenAlle geneesmiddelen |
| Roemenië | 15 | 0 | 15 | BedrijvenAlle geneesmiddelen |
| Saoedi-Arabië | 5 | 5 | 0 | BedrijvenAlle geneesmiddelen |
| Kroatië | 2 | 2 | 0 | BedrijvenAlle geneesmiddelen |
Ook geregistreerd in: Colombia, Duitsland, Frankrijk, Italië, Maleisië, Servië, Singapore, Verenigd Koninkrijk, Zweden
De ATC-groepen waartoe de meeste van zijn geneesmiddelen behoren, grootste eerst.
De werkzame stoffen in de meeste van zijn geneesmiddelen.
Hoe de registers de naam schrijven, genormaliseerd: zonder rechtsvorm, accenten en hoofdletters.
Samengesteld door Prognia uit de openbare geneesmiddelen- en bedrijfsregisters hieronder. Logo’s worden niet gebruikt.
Prognia stelt concerns samen uit de namen die toezichthouders publiceren en uit koppelingen tussen bedrijven; het is geen officiële concernstructuur.
Source: European Medicines Agency (EPAR data).
Licentie: EMA reuse policy (source acknowledgement required)
Fuente de la información: AEMPS (CIMA).
Licentie: AEMPS open data reuse with attribution
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licentie: Public domain (U.S. Government work)
Source: BDPM (ANSM, HAS, UNCAM).
Licentie: Licence Ouverte v1.0
ANVISA / CMED, consumer price table; embedded source date 2026-07-21 and retrieval date
Licentie: Other (Public Domain)
Anvisa published factual open-data CSV https://dados.anvisa.gov.br/dados/CONSULTAS/PRODUTOS/TA_CONSULTA_MEDICAMENTOS.CSV, HTTP version Mon, 12 Oct 2026 11:45:25 GMT; acquired 12 October 2026; original source states and timestamps retained.
Licentie: Brazil federal factual open data, consolidated Decreto 8777/2016 article 4; attribution and third-party exceptions
Anvisa, https://dados.anvisa.gov.br/dados/CONSULTAS/EMPRESA_FISCALIZACAO_PRODUTO/TA_CONSULTA_CBPF_MEDICAMENTO_DETALHE.CSV; source modified Fri, 15 May 2026 07:52:35 GMT; acquired 2026-10-18T08:23:43.211112+00:00; original factual values retained, no endorsement.
Licentie: Brazil federal factual open data, consolidated Decreto 8777/2016 article 4; attribution and third-party exceptions
Anvisa, official medicine/API manufacturer factual export, HTTP source version Fri, 09 Oct 2026 08:21:54 GMT, acquired 2026-10-09; exact unmodified native identifiers and fields preserved.
Licentie: Brazil federal factual open-data reuse; Decreto 8777/2016 consolidated article 4 and third-party exceptions
Agência Nacional de Vigilância Sanitária (Anvisa), DATAVISA open-data register; source modification 2026-10-07, acquired 2026-10-07 UTC.
Licentie: Brazil federal open-data reuse, Decreto 8777/2016, consolidated article 4 as amended by Decreto 9903/2019
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licentie: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licentie: Open Government Licence Canada
Federal Commercial Registry Office;exact dataset/law title,source URI/link and retrieval date;Prognia separately labelled normalization;no endorsement.
Licentie: opendata.swiss terms_by
Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA), Colombia, CUM otros; source update 2026-09-16; acquired 2026-10-08.
Licentie: CC BY-SA 4.0
Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA), Colombia, CUM vencidos; source update 2026-09-16; acquired 2026-10-08.
Licentie: CC BY-SA 4.0
Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA), Colombia, CUM vigentes; source update 2026-09-16; acquired 2026-10-08.
Licentie: CC BY-SA 4.0
Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA), Colombia, CUM vigentes, dataset i7cb-raxc, rowsUpdatedAt 1792152574, acquired 2026-10-26; original values retained.
Licentie: CC BY-SA 4.0
Bundesinstitut für Arzneimittel und Medizinprodukte, pediatric list, acquired 2026-10-29T14:36:58.614273+00:00
Licentie: commercial redistribution permission not established
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licentie: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licentie: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
BDPM / ANSM, HAS and UNCAM; original URLs and each update date retained
Licentie: BDPM exact Licence Ouverte v1.0 (October 2011)
BDPM / ANSM, HAS and UNCAM, CIS_MITM.txt, published 13/10/2026, acquired 2026-10-25T22:15:46.803459+00:00; exact facts retained, no endorsement.
Licentie: BDPM exact Licence Ouverte v1.0 (October 2011)
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 1 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:47.757811+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licentie: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 2 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:48.423930+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licentie: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
GLEIF; exact source URL and retrieval date; no endorsement.
Licentie: CC0
HALMED, Baza lijekova, source export 08.10.2026., acquired 2026-10-08; factual structured adaptation; Otvorena dozvola RH, NN 67/2017.
Licentie: Otvorena dozvola RH
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_A_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:41 GMT; acquired 2026-10-13T17:21:06.055244+00:00; native fields retained, source identifier and role projections are adaptations.
Licentie: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_H_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:40 GMT; acquired 2026-10-13T17:21:06.034935+00:00; native fields retained, source identifier and role projections are adaptations.
Licentie: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.
Licentie: CC BY 4.0; AIFA published open-data catalog
Ministero della Salute, Italy; https://www.dati.salute.gov.it/it/dataset/distributori-di-farmaci/; original CSV snapshot 15 October 2026, acquired 2026-10-15T13:26:43.659718+00:00; adapted factual fields under IODL2. Coordinates: © OpenStreetMap contributors, separate rights gate.
Licentie: Italian Open Data Licence v2.0, exact dataset-catalog assignment; coordinate fields separately attributed to OpenStreetMap
Ministero della Salute, Distributori di farmaci, source file13Oct2026. https://www.dati.salute.gov.it/it/dataset/distributori-di-farmaci/; IODL2.0 https://www.dati.gov.it/content/italian-open-data-license-v20. Original URLs/locators and retrieval timestamps; selected/normalized by Prognia; no government endorsement.
Licentie: Italian Open Data Licence
National Pharmaceutical Regulatory Agency and Ministry of Health Malaysia, KKMNOW Approved Pharmaceutical Products, https://data.moh.gov.my/data-catalogue/pharmaceutical_products; CC BY 4.0; original data as of 2026-09-30 23:59; acquired 2026-10-16T22:34:39.948031+00:00; Prognia preserves original records and projects exact MAL IDs and category/role fields. No government endorsement implied.
Licentie: Creative Commons Attribution 4.0 International (CC BY 4.0), exact MOH dataset dedication
College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.
Licentie: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim
Contains data under the Norwegian licence for Open Government data (NLOD) distributed by Brønnøysundregistrene. https://data.norge.no/nlod/en/2.0; original API URLs, retrieval dates and locators. Selected and normalized by Prognia; fractional JSON numbers preserved as labelled exact decimal strings.
Licentie: Norwegian Licence for Open Government Data
Ministerul Sănătății, Catalogul public naţional al preţurilor, 18 iunie 2021, downloaded 2026-10-08 from data.gov.ro; CC BY 4.0; structured factual adaptation, code whitespace trimmed only where explicitly recorded.
Licentie: Creative Commons Attribution 4.0 International (CC BY 4.0)
Oficiul Național al Registrului Comerțului; exact original source URLs, snapshot2026-09-02 where applicable, retrieval date, original record locators; https://creativecommons.org/licenses/by/4.0/
Licentie: Creative Commons Attribution
ALIMS, Registar humanih lekova, source 08.10.2026 02:00, downloaded 2026-10-08, https://data.gov.rs/sr/datasets/lekovi-za-upotrebu-u-khumanoj-meditsini/; structured factual adaptation; Serbian Open Data Licence.
Licentie: Serbian Open Data Licence (sodl)
Saudi Food and Drug Authority (SFDA), foreign human medicine open-data listing, source scope 2023, retrieved 11 October 2026 UTC; exact original file and response modification date retained.
Licentie: Exact SFDA open-data section explicitly offers freely usable named human medicine workbooks; factual-data scope only
Läkemedelsverket, Sweden, Förvaringstemperatur och hållbarhet, source extract 2026-10-20, acquired 2026-10-20T20:46:08.868635+00:00. Original cells retained; structured adaptation by Prognia. No regulator endorsement.
Licentie: Creative Commons Attribution 4.0 International (CC BY 4.0)
Läkemedelsverket, Sweden, Läkemedelsprodukter, source extract 2026-10-20, acquired 2026-10-20T20:45:53.483733+00:00. Original cells retained; structured adaptation by Prognia. No regulator endorsement.
Licentie: Creative Commons Attribution 4.0 International (CC BY 4.0)
Contains information from HSA Listing of Registered Therapeutic Products accessed on 8 October 2026 from data.gov.sg, under Singapore Open Data Licence 1.0: https://data.gov.sg/open-data-licence
Licentie: Singapore Open Data Licence
FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.
Licentie: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions
Meld een fout of vraag verwijdering aanCorrecties van het bedrijf zelf zijn welkom.
Houd de geneesmiddelen van UCB op Prognia juist, zie hoe zorgprofessionals ze gebruiken en beantwoord wat ze vragen. Een gesprek van 20 minuten, in het Engels.
Plan een gesprekBekende farmaceutische concerns, elk met al zijn bedrijven.